Kineta
Aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas. Learn more
Launch date
Employees
Market cap
CAD12.8m
Enterprise valuation
CAD13m (Public information from Sep 2024)
Share price
$0.7 KA
Seattle Washington (HQ)
Authorizing premium user...